secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0000318154-25-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q4 revenue up 11% to $9.1B; non-GAAP EPS $5.31 (+13%)
-----------------------------------------------------------

- Q4 product sales up 11% (14% volume growth); FY product sales up 19% (23% volume growth).
- GAAP EPS $1.16 vs $1.42; FY $7.56 vs $12.49, driven by mark-to-market losses on equity investments.
- Non-GAAP EPS $5.31 vs $4.71; FY $19.84 vs $18.65, driven by higher revenues offset by higher expenses.
- Full-year free cash flow $10.4B vs $7.4B in 2023, driven by business performance and working capital timing.
- 21 products achieved record full-year sales; rare disease sales $1.2B in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/0000318154-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/amgn-20250204.htm
  HTML page:      https://secwatch.observer/filing/0000318154-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer